10:04 IST
NSE
Business Update
Wanbury Business Update
Wanbury Limited received a 'No DMF deficiency' letter from the USFDA for multiple ANDAs. This clearance facilitates expansion into the South Korean API market.
Wanbury Ltd
Wanbury Ltd news stories on ALFA NewsRead the news →- Share price
- ₹198.70
- Market cap
- ₹694.8 Cr
- Revenue (annual)
- ₹650.3 Cr
- Net profit (annual)
- ₹66.13 Cr
- P/E (TTM)
- 12.4×Sector 47.3×
- Promoter holding
- 43.02%+0.00% QoQ
- FII holding
- 0.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Business Update 4Board Meeting Date 4Management Change 3Financial Results 3Annual General Meeting 3Share Pledge 2Results Update 2Product Launch 2Debt & Borrowing 2Price Movement Clarification 1Merger & Restructuring 1Legal & Regulatory 1Employee Stock Options 1Earnings Call 1
Time
4 announcements with these filters
16:05 IST
NSE
Business Update
Wanbury Business Update
Wanbury Limited announced that the USFDA completed a cGMP inspection at its Tanuku facility, resulting in a Form 483 with six observations.
12:36 IST
NSE
Business Update
Wanbury Business Update
Wanbury Limited's Tanuku site successfully completed Australia's TGA inspection. This regulatory milestone enables the company to export three additional APIs to the Australian market.
17:47 IST
NSE
Business Update
Wanbury Business Update
Wanbury Limited's Patalganga site successfully completed a Korea FDA (MFDS) regulatory inspection with zero observations. The inspection, conducted from April 7 to April 9, 2026, confirms cGMP compliance. This approval follows previous zero-observation inspections by the USFDA and Anvisa, reinforcing the company's manufacturing compliance standards.